Skip to content
Parker Institute for Cancer Immunotherapy
Search
Search Close

Research Projects

Our research team aims to answer immunotherapy’s most fundamental questions. What happens to the immune system when a patient gets cancer? How can we make immunotherapy kill all types of tumors so more patients can live a cancer-free life? We work with the best in academia and industry to find answers, fast. And we’re building an arsenal of new tools – from cancer vaccines to next-gen cell therapies – so we can end cancer. For good.

80

Research Collaborators

142

PICI-Supported research projects

What We Do

  • Science, unlocked. If cancer is a puzzle, immunotherapy could be the key. To unlock the answers, we study the fundamental science at the intersection of immunology and cancer.
  • A collaborative force. We bring together the best players from different disciplines – including immunology, oncology, chemistry and engineering – to generate solutions using multiple perspectives.
  • Speed up science for patients. We support pre-clinical research programs that directly translate to the clinic so that discoveries can more quickly turn into new treatments for patients.
  • Build new weapons to fight cancer. With our partners, we develop novel treatments such as therapeutic vaccines and cell therapies, from the ground up.

Meet Our Experts

Research

John Connolly, PhD
Chief Scientific Officer

Samantha Bucktrout, PhD
Senior Director, Research

Lisa Butterfield, PhD
Vice President, Research and Development

Translational Research

Theresa LaVallee, PhD
Vice President, Translational Medicine and Regulatory Affairs

Informatics

Lacey Kitch, PhD
Head of Informatics

Christine (Chris) Spencer, PhD
Associate Director, Informatics

Research Operations

Christopher Perry
Associate Director, Biospecimen Operations

Research Projects

CANDEL

A first-of-its-kind data analysis engine for scientific discovery.

REVIVE

Can we outsmart cancer by learning from the past?

TRIBUTE

A data-driven approach to metastatic triple negative breast cancer

Brain Tumor Program

Tackling one of the toughest disease sites to unlock the promise of cell and gene therapy in solid tumors